vs
安捷伦科技（A）与Aardvark Therapeutics, Inc.（AARD）财务数据对比。点击上方公司名可切换其他公司
安捷伦科技是全球知名的生命科学、诊断与应用化学领域解决方案提供商，旗下生命科学与应用市场业务板块提供液相色谱系统及组件、液相色谱质谱联用系统、气相色谱设备、电感耦合等离子体质谱仪、原子吸收仪等多种分析检测仪器，服务全球各领域客户。
Aardvark Therapeutics是一家处于临床阶段的生物制药企业，专注于研发针对炎症、代谢类疾病及罕见病的新型靶向疗法，核心管线聚焦G蛋白偶联受体相关药物，主要服务北美及全球患者群体，开展医药研发领域合作。
A vs AARD — 直观对比
营收规模更大
A
是对方的Infinity倍
$0
损益表 — Q1 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.8B | $0 |
| 净利润 | $305.0M | $-17.6M |
| 毛利率 | 52.6% | — |
| 营业利润率 | 19.6% | — |
| 净利率 | 17.0% | — |
| 营收同比 | 7.0% | — |
| 净利润同比 | -4.1% | — |
| 每股收益（稀释后） | $1.07 | $-0.81 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AAARD
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.9B | $0 | ||
| Q3 25 | $1.7B | $0 | ||
| Q2 25 | $1.7B | $0 | ||
| Q1 25 | $1.7B | $0 | ||
| Q4 24 | $1.7B | — | ||
| Q3 24 | $1.6B | — | ||
| Q2 24 | $1.6B | — |
净利润AAARD
| Q1 26 | $305.0M | — | ||
| Q4 25 | $434.0M | $-17.6M | ||
| Q3 25 | $336.0M | $-16.3M | ||
| Q2 25 | $215.0M | $-14.4M | ||
| Q1 25 | $318.0M | $-9.3M | ||
| Q4 24 | $351.0M | — | ||
| Q3 24 | $282.0M | — | ||
| Q2 24 | $308.0M | — |
毛利率AAARD
| Q1 26 | 52.6% | — | ||
| Q4 25 | 53.2% | — | ||
| Q3 25 | 51.1% | — | ||
| Q2 25 | 51.9% | — | ||
| Q1 25 | 53.5% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 54.2% | — | ||
| Q2 24 | 54.4% | — |
营业利润率AAARD
| Q1 26 | 19.6% | — | ||
| Q4 25 | 23.8% | — | ||
| Q3 25 | 20.7% | — | ||
| Q2 25 | 18.0% | — | ||
| Q1 25 | 22.4% | — | ||
| Q4 24 | 24.0% | — | ||
| Q3 24 | 21.1% | — | ||
| Q2 24 | 23.1% | — |
净利率AAARD
| Q1 26 | 17.0% | — | ||
| Q4 25 | 23.3% | — | ||
| Q3 25 | 19.3% | — | ||
| Q2 25 | 12.9% | — | ||
| Q1 25 | 18.9% | — | ||
| Q4 24 | 20.6% | — | ||
| Q3 24 | 17.9% | — | ||
| Q2 24 | 19.6% | — |
每股收益（稀释后）AAARD
| Q1 26 | $1.07 | — | ||
| Q4 25 | $1.53 | $-0.81 | ||
| Q3 25 | $1.18 | $-0.75 | ||
| Q2 25 | $0.75 | $-0.66 | ||
| Q1 25 | $1.11 | $-0.71 | ||
| Q4 24 | $1.23 | — | ||
| Q3 24 | $0.97 | — | ||
| Q2 24 | $1.05 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.8B | $110.0M |
| 总债务越低越好 | $3.0B | — |
| 股东权益账面价值 | $6.9B | $106.6M |
| 总资产 | $12.8B | $117.2M |
| 负债/权益比越低杠杆越低 | 0.44× | — |
8季度趋势，按日历期对齐
现金及短期投资AAARD
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.8B | $110.0M | ||
| Q3 25 | $1.5B | $126.3M | ||
| Q2 25 | $1.5B | $141.8M | ||
| Q1 25 | $1.5B | $151.3M | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.8B | — | ||
| Q2 24 | $1.7B | — |
总债务AAARD
| Q1 26 | $3.0B | — | ||
| Q4 25 | $3.0B | — | ||
| Q3 25 | $3.4B | — | ||
| Q2 25 | $3.3B | — | ||
| Q1 25 | $3.3B | — | ||
| Q4 24 | $3.3B | — | ||
| Q3 24 | $2.1B | — | ||
| Q2 24 | $2.1B | — |
股东权益AAARD
| Q1 26 | $6.9B | — | ||
| Q4 25 | $6.7B | $106.6M | ||
| Q3 25 | $6.4B | $122.4M | ||
| Q2 25 | $6.1B | $136.9M | ||
| Q1 25 | $6.0B | $150.7M | ||
| Q4 24 | $5.9B | — | ||
| Q3 24 | $5.9B | — | ||
| Q2 24 | $6.2B | — |
总资产AAARD
| Q1 26 | $12.8B | — | ||
| Q4 25 | $12.7B | $117.2M | ||
| Q3 25 | $12.2B | $133.2M | ||
| Q2 25 | $12.2B | $147.5M | ||
| Q1 25 | $11.9B | $157.0M | ||
| Q4 24 | $11.8B | — | ||
| Q3 24 | $11.0B | — | ||
| Q2 24 | $10.9B | — |
负债/权益比AAARD
| Q1 26 | 0.44× | — | ||
| Q4 25 | 0.45× | — | ||
| Q3 25 | 0.53× | — | ||
| Q2 25 | 0.55× | — | ||
| Q1 25 | 0.56× | — | ||
| Q4 24 | 0.57× | — | ||
| Q3 24 | 0.36× | — | ||
| Q2 24 | 0.34× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $268.0M | $-16.8M |
| 自由现金流经营现金流 - 资本支出 | $175.0M | — |
| 自由现金流率自由现金流/营收 | 9.7% | — |
| 资本支出强度资本支出/营收 | 5.2% | — |
| 现金转化率经营现金流/净利润 | 0.88× | — |
| 过去12个月自由现金流最近4个季度 | $993.0M | — |
8季度趋势，按日历期对齐
经营现金流AAARD
| Q1 26 | $268.0M | — | ||
| Q4 25 | $545.0M | $-16.8M | ||
| Q3 25 | $362.0M | $-16.1M | ||
| Q2 25 | $221.0M | $-9.8M | ||
| Q1 25 | $431.0M | $-11.4M | ||
| Q4 24 | $481.0M | — | ||
| Q3 24 | $452.0M | — | ||
| Q2 24 | $333.0M | — |
自由现金流AAARD
| Q1 26 | $175.0M | — | ||
| Q4 25 | $452.0M | — | ||
| Q3 25 | $259.0M | $-16.1M | ||
| Q2 25 | $107.0M | $-9.9M | ||
| Q1 25 | $334.0M | — | ||
| Q4 24 | $388.0M | — | ||
| Q3 24 | $360.0M | — | ||
| Q2 24 | $230.0M | — |
自由现金流率AAARD
| Q1 26 | 9.7% | — | ||
| Q4 25 | 24.3% | — | ||
| Q3 25 | 14.9% | — | ||
| Q2 25 | 6.4% | — | ||
| Q1 25 | 19.9% | — | ||
| Q4 24 | 22.8% | — | ||
| Q3 24 | 22.8% | — | ||
| Q2 24 | 14.6% | — |
资本支出强度AAARD
| Q1 26 | 5.2% | — | ||
| Q4 25 | 5.0% | — | ||
| Q3 25 | 5.9% | — | ||
| Q2 25 | 6.8% | — | ||
| Q1 25 | 5.8% | — | ||
| Q4 24 | 5.5% | — | ||
| Q3 24 | 5.8% | — | ||
| Q2 24 | 6.5% | — |
现金转化率AAARD
| Q1 26 | 0.88× | — | ||
| Q4 25 | 1.26× | — | ||
| Q3 25 | 1.08× | — | ||
| Q2 25 | 1.03× | — | ||
| Q1 25 | 1.36× | — | ||
| Q4 24 | 1.37× | — | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.08× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
A
| Service Other | $525.0M | 29% |
| Chemicaland Energy Market | $422.0M | 23% |
| Agilent Cross Lab | $273.0M | 15% |
| Environmentaland Forensics Market | $177.0M | 10% |
| Food Market | $166.0M | 9% |
| Academiaand Government Market | $130.0M | 7% |
| Applied Markets | $98.0M | 5% |
AARD
暂无分部数据
